


National Hospital of Obstetrics and Gynecology



HPV DNA primary in cervical cancer screening What benefits for patients?

Prof. Vu Ba Quyet

Director of National O&G hospital

Vice President of Vietnam Association of Gynecology & Obstetrics




BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

Cervical cancer screening Patient expectation?






Cervical Cancer progression






National Hospital of Obstetrics and Gynecology

Model of screening Patient benefit centric






Cervical cancer screening: Cytology based





National Hospital of Obstetrics and Gynecology

Cytology




Dr. George M. Papanicolaou 1883-1962

- Low sensitivity # 40-75%
- Results depend on cytologist expertise
- Big investment because of high cost for training and educating specialists



National Hospital of Obstetrics and Gynecology


Cervical Cancer screening Identify root cause: HPV is the main cause





BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

Cervical Cancer is caused by hrHPV persistent infection



HPV16 & HPV18 are the most prevalence oncogenic genotypes



- HPV infection is present in almost cases of cervical, pre-cancer, CIN and high grade of lesion
- Persistent infection 1 of 14 of high-risk HPV genotypes causes greater than 99% of all cervical cancer cases



National Hospital of Obstetrics and Gynecology

Cervical cancer screening

HPV based

			indicat testing v	, HPV was ed for co- vith pap for n >30 yo.	In 2014 H was appro primary so test for wor 25 year	oved as creening men from
Introduced in 1940s		In1999, HPV was indicated for ASCUS triage			J	
1927 1940	1960s	1990s	2000s	2010s	2010	
Fist introduced in 1927 by Babes	Pap become widely adopted over the world and considered as a effectiveness method, reduced cervical cancer rate					



National Hospital of Obstetrics and Gynecology

HPV primary screening





National Hospital of Obstetrics and Gynecology

HPV primary screening Progression over the world


Chương trình quốc gia Chương trình mục tiêu/vùng Chương dẫn Mghiên cứu thí điểm/Khác Current to the best of our knowledge on 27APR17; South Korea, Taiwan – co-testing but not stand-alone primary screening

Shun.



BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

HPV DNA based screening





HPV DNA as the primary screening test All clinical trials find the similar results

- Several randomized clinical trials in Europe– NTCC, POBOSCAM, VUSA, ARTISTIC, SWEDESCREEN, Finnish Screening Trial
- One observational clinical from the US ATHENA
- Kaiser. clinical NCI's Kaiser N. California study
- All demonstrated that HPV primary screening is safe and effectiveness




HPV as the primary screening test in the US ATHENA trial, women >25 years old

- Studied 42,208 women <a>25 in the US
- Had gynaecology exam, LBC, HPV (with genotyping)
- Colposcopy for all women with HPV (+), and/or LBC (+) and a randomized subgroup of hrHPV (-)
- First large US study of HPV based screening

Wright et al. (2011) Am J Clin Path




ATHENA trial: Study design





Risk of CIN 3/ Cancer of group with PAP (-), HPV(-) Kaiser N. California; 1,011,092 women <a>>30 yrs





Comparison of test's sensitivity

- Systematic review of cohort studies
- Calculation of sensitivity and specificity

	HPV	Cytology
Sensitivity	95% (95% Cl:84 -98)	70% (95% Cl: 54 – 81)
Specificity	84% (95% Cl: 72-91)	95% (95% Cl 92 – 97)

IFCPC2017 World Congress presentation




BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

Cervical cancer screening guidelines: Balancing between benefits versus harm

Goal:

- Minimal mortality and morbidity
- Optimal strategy should:
 - Identify precursors that likely progress to cervical cancer
 - Avoid to detection and unnecessary treatment of infections & lesions that are not tendency become cancerous





How to balance benefits & harm

- Be confident in a negative result
 - Use clinical validated HPV DNA test with internal cellularity control.
- Managing positive result
 - Use proven screening strategies




Clinical validation of HPV DNA test

- HPV infections are very common, about 80% of sexually active women become infected:
 - Almost of infections do not cause a problem
 - The goal is not identify all of cases of HPV infection
 - The goal is identify infected women who currently have CIN2 of wha are at increased risk of developing of CIN 2 in the future.
- Clinical validation helps to maximizes HPV detections that have clinical relevant and minimize unnecessary intervention




Internal Cellularity control





Risk of CIN 3 with negative test 1,011,092 women aged 30-64 years



Gage JC, et al. J Natl Cancer Inst. 2014;106(8):dju153.




Conclusion 1

HPV DNA as primary screening offers strong prevention and safety for patients/women



BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

Patient benefit centric





Comparing different strategies

- Based on the complete 3 year follow-up data, we evaluated the performance of 3 different screening algorithms in women <u>></u>25 years
- Evaluated Strategies were:
 - Cytology
 - HPV primary screening with HPV 16/18 genotyping
 - Co-testing*

Wright, et al. Gynecol Oncol. 2015 doi:10.1016/j.ygyno.2014.11.076



Comparison of strategies for women <u>></u>25 years olds *CIN3+ were identified and colposcopy*

Strategy	Screening tests	CIN3+ at baseline	CIN 3+ Year 1-3	Colposcopy	Colposcopy per CIN3
cytology	45,166	143	36	1,934	10.8
Co-testing	82,994	143	97	3,097	12.9
HPV primary	52,651	197	97	3,769	12.8

Total women ≥CIN3 =347



Comparision of screening strategies

Value for patients

Attribute	PAP	Co-testing	HPV Primary
Level of protection	Low	High	High
Cost	1x test	2x tests	1x test
Complexity	High	High	Low
Number of colposcopy	Low	High	High
Interval	Short	Long	Long




Conclusion 2

HPV DNA primary screening offers cost effectiveness with high protection and long interval for patients/women



BỆNH VIỆN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

Patient benefit centric





Hospital of Obstetrics and Gynecology

Coverage of HPV DNA

- Almost O&G hospitals have HPV DNA test
- Effective sample collection system covering nationwide




Conclusion 3

HPV DNA with high coverage and effective sample collection process that facilitates the accessibility and comfort for patients/women



HPV DNA highly and widely recommended





BÊNH VIÊN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

ASCO Resource Stratified Guidelines for Cervical Cancer Secondary Prevention

	Basic	Limited	Enhanced	Maximal
Screen	HPV DNA test; if not available VIA	HPV DNA test	HPV DNA test	HPV DNA test (Co-testing an option)
Age Range	30-49	30-49	30-65	25-65
Frequency	1-3 screenings per lifetime	Every 10 years	5 years; if negative x2 then 10 years	5 years
Triage	VAT	HPV 16/18 GT or cytology or VAT	HPV 16/18 GT or cytology	HPV 16/18 GT or cytology
Triage (-)	f/u 12 months	f/u 12 months	f/u 12 months	f/u 12 months
Triage (+)	Treat	Colpo or VAT (if Colpo not available)	Colpo	Colpo

VIA – visual inspection with acetic acid; VAT – visual assessment and treatment https://pilotguidelines.atlassian.net/wiki– accessed 06JUN2017



BÊNH VIÊN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

ASCO Resource Stratified Guidelines for Cervical Cancer Secondary Prevention


	Basic	Limited	Enhanced	Maximal
Screen	HPV DNA test; if not available VIA	HPV DNA test	HPV DNA test	HPV DNA test (Co-testing an option)
Age Range	30-49	30-49	30-65	25-65
Frequency	1-3 screenings per lifetime	Every 10 years	5 years; if negative x2 then 10 years	5 years
Triage	VAT	HPV 16/18 GT or cytology or VAT	HPV 16/18 GT or cytology	HPV 16/18 GT or cytology
Triage (-)	f/u 12 months	f/u 12 months	f/u 12 months	f/u 12 months
Triage (+)	Treat	Colpo or VAT (if Colpo not available)	Colpo	Colpo

VIA – visual inspection with acetic acid; VAT – visual assessment and treatment

https://pilotguidelines.atlassian.net/wiki-accessed 06JUN2017




US HPV Primary Screening Algorithm






National program of Australia Starting by HPV





Vietnam guideline: HPV primary






BÊNH VIÊN PHỤ SẢN TRUNG ƯƠNG National Hospital of Obstetrics and Gynecology

National O&G guideline



Dựa trên Kế hoạch hành động quốc gia về dự phòng và kiếm soát ung thự cổ từ cung giai doạn 2016 - 2025 đã được Bộ Y tế phê duyệt, Bệnh viện Phụ sản Trung Ương biên soan Hưởng dẫn Dự phòng cấp 2 phù hợp với tính hình thực tế về cơ sở vật chất cũng như các nguồn lực khác sẵn có của bệnh viện. **Các phác đồ sàng lọc ung thư cổ tử cung** Phác đồ 2: Sàng lọc dựa vào xét nghiệm HPV (định típ từng phần)⁴

Áp dụng cho phụ nữ từ 25 tuổi trở lên, đã có quan hệ tình dục



* 12 hr HPV (12 high-risk HPV) 12 tip HPV nguy cơ cao khác: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68



Conclusion

- HPV primary screening in cervical cancer screening offers strong prevention and safety, cost effectiveness and convenience for patients/women
- HPV primary screening startegy based on the balance between risks and harm
 - Clinical validated tests with proven longitudinal safety and internal cellularity control
 - Appropriate interval screening
- HPV DNA is becoming popular and convenient for patients/women to access because of high coverage and effective sample collection process.



National Hospital of Obstetrics and Gynecology

Thank you for your attention!

CERVICALCANCER AWARENESS

NEVER GIVE UPI